Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00388414 |
Recruitment Status :
Completed
First Posted : October 16, 2006
Results First Posted : December 11, 2017
Last Update Posted : December 11, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Low Back Pain | Drug: duloxetine Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Functional MRI Neural Correlates of Medication Efficacy in Patients With Chronic Low Back Pain |
Study Start Date : | September 2006 |
Actual Primary Completion Date : | January 2010 |
Actual Study Completion Date : | January 2010 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo - sugar pill |
Drug: Placebo
Placebo pill once daily |
Experimental: Duloxetine |
Drug: duloxetine
30-60mg of duloxetine daily |
- Pain [ Time Frame: 3 months ]
Brief Pain Inventory (BPI) scores were obtained at baseline, weeks 1, 2, 6, 7, 8, and 12, and a follow-up visit one week after completing the study.
Responses are rated on a scale from 0-10, with 0 = no pain and 10 = pain as bad as you can imagine.
Placebo and duloxetine pain scores calculated by averaging pain scores from each visit after baseline.
Values were converted to percent change in pain: [(baseline pain - end point pain)/baseline pain] x 100.
- Neural Correlates of Pain Relief [ Time Frame: 3 months ]
Scores reflect the average connectivity strength of that region of interest to the rest of the cortex.
There were no minimum or maximum values on this scale. Higher scores reflect stronger connectivity, and lower scores reflect less connectivity (all scores fell within -3 and 3).
Subscales are averaged.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:- Males aged 18-60
- Back Pain
- Must be able to comply with study visit schedule and other study requirements
- Capable of performing the experimental tasks Exclusion Criteria:- Contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)
- Known hypersensitivity to duloxetine or any of the inactive ingredients
- Uncontrolled narrow-angle glaucoma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388414
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Sean Mackey | Stanford University |
Responsible Party: | Sean Mackey, Redlich Professor, Stanford University |
ClinicalTrials.gov Identifier: | NCT00388414 |
Other Study ID Numbers: |
F1J-MC-I006 |
First Posted: | October 16, 2006 Key Record Dates |
Results First Posted: | December 11, 2017 |
Last Update Posted: | December 11, 2017 |
Last Verified: | November 2017 |
Back Pain Low Back Pain Pain Neurologic Manifestations Duloxetine Hydrochloride Serotonin and Noradrenaline Reuptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |
Neurotransmitter Agents Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Antidepressive Agents Psychotropic Drugs Dopamine Agents |